Loading organizations...
Hillhouse Investment is a global investment firm managing private equity, public equities, and venture capital across all stages of a company's life cycle, headquartered in Beijing, China, with additional offices in major financial hubs. The firm employs an in-depth fundamental research approach to identify opportunities, with a primary focus on Asia and selective investments worldwide across diverse sectors including healthcare, technology, and consumer. As of March 2023, Hillhouse managed $62 billion in assets under management, drawing capital from prominent institutional investors such as the Yale University Endowment and Canada Pension Plan Investment Board (CPPIB). Its diverse portfolio features significant stakes in recognizable companies like Tencent, JD.com, Baidu, and Zoom, reflecting its strategy of investing in sustainable businesses. The firm was established in 2005 by Zhang Lei, commencing operations with $20 million in seed capital provided by Yale University's endowment.
Key people at Hillhouse Investment.
Hillhouse Investment was established in Asia in 2005, and it began by investing globally in public equities.
The firm partners with exceptional management teams, leveraging its investment experience to help these organizations grow and achieve long-term success.
Hillhouse Investment was established in Asia in 2005, and it began by investing globally in public equities.
The firm partners with exceptional management teams, leveraging its investment experience to help these organizations grow and achieve long-term success.
Key people at Hillhouse Investment.
Hillhouse Investment is an investment firm that was established in Asia in 2005. From its inception, the firm adopted a strategic focus on making long-term investments, initially concentrating its efforts on public equities across global markets. This foundational approach underscores a commitment to patient capital and a deep understanding of market fundamentals, which has guided its investment thesis over time.
The firm's operational model is built upon the principle of close collaboration with management teams. Hillhouse Investment actively partners with the leadership of the businesses it supports, aiming to leverage its comprehensive investment experience. This partnership is designed to provide strategic insights and resources that facilitate growth and operational excellence within these organizations.
A key objective for Hillhouse Investment is to identify and support high-quality businesses. The firm works to help these companies not only grow but also to thrive in competitive environments, ensuring their development is sustainable. This involves a commitment to understanding the unique challenges and opportunities each business faces.
Hillhouse Investment's overarching philosophy is centered on building organizations that are robust and capable of standing the test of time. This long-term perspective is integral to its investment decisions and its engagement strategies, fostering resilience and enduring value creation. The firm aims to contribute to the global expansion and sustained success of the entities within its portfolio.
By focusing on long-term partnerships and fundamental value, Hillhouse Investment seeks to create lasting impact. Its approach emphasizes a deep commitment to the businesses it invests in, working alongside them to achieve their strategic goals and ensure their continued relevance and prosperity in the global economy.
Hillhouse Investment has 2 tracked investments across 2 companies. The latest tracked deal is $52.0M Series A in Third Arc Bio in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 4, 2026 | Third Arc Bio | $52.0M Series A | Andreessen Horowitz | AbbVie, Aberdeen Investments, Alderline Group, Biotechnology Value Fund, Galapagos, Goldman Sachs Alternatives, Marshall Wace, Omega Funds, T. Rowe Price, Abrdn, BVF Partners, Freepoint Capital Group, 高盛 |
| Jan 28, 2026 | Tenpoint Therapeutics | $85.0M Series B | British Business Bank, EQT, Hillhouse Investment, Janus Henderson Investors | AdBio Partners, Eight Roads Ventures, EQT Life Sciences, F Prime, Qiming Venture Partners USA, Sofinnova Partners, Wille Finance |
